Yield10 Bioscience Beheer

Beheer criteriumcontroles 3/4

De CEO Yield10 Bioscience is Olly Peoples, benoemd in Oct2016, heeft een ambtstermijn van 8.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 598.55K, bestaande uit 57.5% salaris en 42.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.02% van de aandelen van het bedrijf, ter waarde $ 10.97K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.1 jaar en 12.9 jaar.

Belangrijke informatie

Olly Peoples

Algemeen directeur

US$598.6k

Totale compensatie

Percentage CEO-salaris	57.5%
Dienstverband CEO	8.1yrs
Eigendom CEO	3.0%
Management gemiddelde ambtstermijn	8.1yrs
Gemiddelde ambtstermijn bestuur	12.9yrs

Recente managementupdates

Recent updates

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Aug 10

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Nov 12

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Jul 19

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 18

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Apr 14

Analyse CEO-vergoeding

Hoe is Olly Peoples's beloning veranderd ten opzichte van Yield10 Bioscience's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$13m
Mar 31 2024	n/a	n/a	-US$13m
Dec 31 2023	US$599k	US$344k	-US$14m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$14m
Mar 31 2023	n/a	n/a	-US$14m
Dec 31 2022	US$527k	US$331k	-US$14m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$315k	-US$11m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	US$1m	US$289k	-US$10m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$600k	US$275k	-US$13m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$738k	US$275k	-US$9m
Sep 30 2018	n/a	n/a	-US$11m
Jun 30 2018	n/a	n/a	-US$11m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$382k	US$225k	-US$11m

Compensatie versus markt: De totale vergoeding ($USD 598.55K ) Olly } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Olly is gestegen terwijl het bedrijf verliesgevend is.

CEO

Olly Peoples (66 yo)

8.1yrs

Tenure

US$598,554

Compensatie

Dr. Oliver P. Peoples, also known as Olly, Ph D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Oliver Peoples	Co-Founder	8.1yrs	US$598.55k	3.02% $ 11.0k
Lynne Brum	VP of Planning & Corporate Communications and Secretary	8.1yrs	US$366.98k	1.81% $ 6.6k
Charles Haaser	VP of Finance	10yrs	US$251.94k	0.87% $ 3.2k

8.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YTEN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Oliver Peoples	Co-Founder	32.4yrs	US$598.55k	3.02% $ 11.0k
Richard Hamilton	Independent Director	7.7yrs	US$74.84k	0.44% $ 1.6k
Robert Van Nostrand	Independent Chairman of the Board	18.1yrs	US$84.84k	0.29% $ 1.1k
Anthony Sinskey	Independent Director	32.4yrs	US$74.84k	0.39% $ 1.4k
Sherri Brown	Independent Director	4.8yrs	US$57.34k	0% $ 0
Willie Loh	Independent Director	2.1yrs	US$57.34k	0% $ 0

12.9yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YTEN zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.9 jaar).

Yield10 Bioscience Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Recent updates

Yield10 Bioscience, Inc. announced that it has received $3 million in funding

Nuseed Nutritional US Inc. entered into an asset purchase agreement to acquire Substantially all assets of Yield10 Bioscience, Inc./Yield10 Oilseeds, Inc. from Yield10 Bioscience, Inc. (OTCPK:YTEN) and Yield10 Oilseeds, Inc. for $5 million.

Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from NASDAQ Composite Index

Yield10 Bioscience Announces Delisting from Nasdaq

Yield10 Bioscience Announces 1-for-24 Reverse Stock Split to Increase the Market Price Per Share of the its Common Stock to Maintain the Listing of its Common Stock on The Nasdaq Capital Market

Yield10 Bioscience, Inc., Annual General Meeting, Jun 07, 2024

Yield10 Bioscience Receives Written Notice from The Nasdaq Stock Market LLC Regarding Not Eligible for Second 180 Day Compliance Period for the Minimum Bid Price Rule Deficiency

Yield10 Bioscience, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Yield10 Bioscience, Inc. Announces the Plant Biosafety Office of the Canadian Food Inspection Agency Clear Genome-edited E3902 Camelina for Planting in Canada

Nasdaq Hearings Panel Grants Yield10 Bioscience, Inc. an Additional Extension to Remain Listed on the Nasdaq Capital Market Until May 13, 2024

Yield10 Bioscience, Inc. Provides an Update on Its Omega-3 Camelina Program

Yield10 Bioscience, Inc. Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

Yield10 Bioscience Receives Non-Compliance Notice From Nasdaq

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. Contemplates Bankruptcy.

Yield10 Bioscience, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Yield10 Bioscience, Inc. Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Yield10 Bioscience, Inc. Receives Non-Compliance Notice from Nasdaq

Yield10 Bioscience, Inc. has completed a Composite Units Offering in the amount of $3.7375 million.

Price target decreased by 33% to US$9.83

Second quarter 2023 earnings released: US$0.64 loss per share (vs US$0.70 loss in 2Q 2022)

New major risk - Shareholder dilution

Yield10 Bioscience, Inc. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Market cap size

Yield10 Bioscience, Inc. Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina

New minor risk - Share price stability

Yield10 Bioscience Files Request for Regulatory Status Review Under Usda-Aphis’S Secure Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Yield10 Bioscience Receives A Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insider recently bought US$1m worth of stock

Yield10 Bioscience, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$14.67

Yield10 Bioscience, Inc. Begins Winter 2022/2023 Field Test and Seed Production Program

Yield10 Bioscience, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Yield10 Bioscience, Inc. Appoints Willie Loh to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience GAAP EPS of $0.70 beats by $1.39, revenue of $0.1M misses by $0.06M

Yield10 Bioscience, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Yield10 Bioscience, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$15.33

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Yield10 Bioscience, Inc., Annual General Meeting, May 25, 2022

Price target decreased to US$17.00

Yield10 Bioscience Announces Recent Advances in the Development of Camelina as A Production Platform for PHA Bioplastic

Yield10 Bioscience, Inc. Announces an Update on the Camelina Line E3902 Development Program

Yield10 Bioscience, Inc. to Report Q4, 2021 Results on Mar 09, 2022

Is Yield10 Bioscience (NASDAQ:YTEN) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.87 loss in 3Q 2020)

Consensus revenue estimates fall to US$890.0k

Price target decreased to US$21.50

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.92 loss in 2Q 2020)

Yield10 Bioscience (NASDAQ:YTEN) Is In A Good Position To Deliver On Growth Plans

Yield10 Bioscience, Inc. Begins 2021 Field Test and Seed Scale Up Program

Yield10 Bioscience, Inc.'s (NASDAQ:YTEN) CEO Will Probably Find It Hard To See A Huge Raise This Year

Consensus revenue estimates fall to US$1.08m

First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.12 loss in 1Q 2020)

Here's Why We're Watching Yield10 Bioscience's (NASDAQ:YTEN) Cash Burn Situation

Consensus forecasts updated

Full year 2020 earnings released: US$4.30 loss per share (vs US$35.50 loss in FY 2019)

Yield10 Bioscience, Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day high: US$18.86

Yield10 Bio secures $12.7M capital raise